Patients undergoing treatment at a community-based renal dialysis clinic were monitored monthly for hepatitis B surface antigen (HBsAg) and antibody to HBsAg
HBsAg(+), males were more likely to remain HBsAg(+) indefinitely, whereas females were more likely to convert to HBsAg(-) and develop anti-HBs. This was not due to a sex difference in exposure to hepatitis B virus because only patients who became infected while undergoing treatment were included in the analysis. These data are clear evidence of a sex difference in response to hepatitis B virus, which may partially explain the greater incidence of several chronic liver diseases, including primary hepatocellular carcinoma, in males. In most populations the prevalence of chronic carriers of the hepatitis B virus (HBV) is greater in males than females. This sex difference was reported in 1966 by Blumberg et al. in three tropical populations (1) and subsequently confirmed by many investigators in studies of blood donor populations (2) (3) (4) (5) (6) (7) (8) , various hospitalized and non-hospitalized populations (9-11), kidney transplant and chronic hemodialysis patients (12) , and residents of institutions for the mentally retarded (13, 14) . Some exceptions to this pattern have been observed (9) , including a study in Greece in which the frequency of detection of the surface antigen of HBV (HBsAg) was higher (but not significantly) in fenales (15) . the prevalences of several HBV-related chronic liver diseases such as chronic active hepatitis, post-necrotic -cirrhosis, and primary hepatocellular carcinoma are also greater in males (16) (17) (18) (19) . Chronic active hepatitis is-of particular interest because one form, lupoid hepatitis, is more common in females, but HBsAg(+) chronic hepatitis is more common in males (20, 21) .
There are fewer reports on the prevalence of antibody to H13sAg (anti-HBs) by sex, but most investigators have not found significant sex differences (22) (23) (24) (25) (24) .
Abbreviations: HBV, hepatitis B virus; HBsAg, surface antigen of HBV; anti-HBs, antibody to HBsAg.
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None of the reported studies of populations analyzed the responses of individual members of the population with respect to the precise time course of HBsAg and anti-HBs.
The purpose of this report is to test, in a group of chronic hemodialysis patients, the null hypothesis that with equal exposure there is no sex difference in response to HBV. The analysis involves only patients who began hemodialysis treatment without detectable HBsAg or anti-HBs and subsequently acquired HBsAg. Because all patients are infected, any differences detected in persistence of HBsAg, or development of anti-HBs, must be due to differences in response.
MATERIALS AND METHODS
Serum samples from patients undergoing chronic hermodialysis at a community-based chronic dialysis clinic in Philadelphia were tested monthly for presence of HBsAg and anti-HBs. The patient population and methods for detecting HBsAg and anti-HBs have been described in detail previously (27) . Sera were screened initially for HBsAg by counter electrophoresis (28) and immunodiffusion (29) and for anti-HBs by passive hemagglutination (30) . To determine the precise times of developrnent and loss of HBsAg, serum samples that were HBsAg(-) and anti-HBs(-) by the above tests were tested by radioimmunoassay (Ausria II) (31) .
Analyses similar to life tables were used to estimate the persistence of HBsAg and development of anti-HBs. Differences between survival curves were determined by the method of Thomas and Grunkemeier (32) . Mean ages were compared by the Mann-Whitney U test (33, pp. 116-127) , and frequencies of seroconversion to HBsAg were compared by the 2 X 2 x2 statistic (33, pp. 196-202) . Data were entered on computer cards, stored, and processed in a Hewlett-Packard minicomputer.
.RESULTS Between November 1970 and October 1974, 160 patients began dialysis treatment without HBsAg or anti-HBs. Seventy-seven of these patients-became HBsAg(+). The frequency of seroconversion to HBsAg(+) was higher in males (49/94, 52%) than females (28/66, 42%), but the difference was not significant. Fig. 1 shows the probability of remaining HBsAg(+) "indefinitely" once a patient has been HBsAg(+) for n months. Males were significantly more likely to remain HBsAg(+) indefinitely (i.e., become chronic carriers) than females. This sex difference was detectable until a patient had been HBsAg(+) for 13 months and was significant for 8 months.
In addition to being less likely to become HBsAg(-), males were also less likely to develop protective titers of anti-HBs. The probabilities of remaining anti-HBs(-) were significantly different 2, 3, and 8 months after becoming HBsAg(+) (Fig.  2) . Three patients, two females and one male, became 2562 Medical Sciences: London and Drew (~~~~~~~~~~~~~~5) (4) .C .34 t l t l 
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FIG. '1. The probability of male or female patients remaining HBsAg(+) indefinitely once detected positive. The numbers in parentheses are the numbers of patients at risk at each time interval. A male dialysis patient who is HBsAg(+) on a single test has a 68% chance of remaining HBsAg(+) indefinitely, whereas the probability for a female patient is 33%. Significance levels for differences between the sexes are shown in the arrows between the curves, as calculated by the method of Thomas and Grunkemeier (32) . The longer a patient is HBsAg(+), the greater his or her chance of remaining HBsAg(+).
HBsAg(-) without subsequently developing detectable levels of anti-HBs. Fig. 3 shows the distribution of ages by sex for the patients studied. No significant age difference between males and females was found. We also compared mean ages according to sex and response to HBV and again found no significant differences. Previously, we reported that there was no association between the type of underlying renal disease and the persistence of HBsAg or the development of anti-HBs (27) . DISCUSSION These data require rejection of the null hypothesis that sex differences in HBsAg and anti-HBs prevalences in hemodialysis patients are not due to sex differences in response to HBV infection. Among 77 patients infected with H.BV while undergoing treatment at a single dialysis clinic, males were signifi- cantly more likely to remain HBsAg(+), whereas females were more likely to develop anti-HBs in response to HBV infection. This difference was not related to sex differences in age or rate of infection. Therefore, it is likely that males (at least those with chronic renal disease) are more susceptible to becoming chronic carriers of HBV and differ from females in their immune response to the virus.
Recently, we reported that recipients of kidney transplants who were anti-HBs(+) prior to surgery had early graft rejection, whereas chronic carriers had delayed rejection. Grafts from male donors were particularly at risk; eight of nine were rejected by patients with anti-HBs within 4 months of transplantation (34) .
These observations, in conjunction with the data reported here, suggest the hypothesis that there is a similarity (crossreactivity) between HBsAg and an antigen on the surface of male cells. Whether or not this is the mechanism of susceptibility, the fact that males are likely to retain the virus longer than females may contribute to the greater risk males have of developing the chronic liver diseases associated with hepatitis B infection. That is, males are more likely to become chronic carriers of HBV and as a consequence more likely to develop The costs of publication of this article were defrayed in part by the payment of page charges from funds made available to support the research which is the subject of the article. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
